WI Harper Group-backed XWPharma Initiates First-in-Human Studies of Treatment-Resistant Depression and Chronic Pain Therapy

WI Harper Group | September 13, 2021 | Source: XWPharma WWI Harper-backed XWPharma, a biopharmaceutical company dedicated to the discovery and development of therapeutics, announced its first-in-human study evaluating XW10508 – the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of depression and chronic…

WI Harper Group-backed XEV and Italy’s ENI Partner for Zero Emission and Zero Charging Time Mobility

WI Harper Group | September 10, 2021 | Source: la Repubblica XEV, a company that manufacturers electric vehicles (EV) through utilizing mature 3D printing technology, has partnered with Ente Nazionale Idrocarburi or ENI (“State Hydrocarbons Authority”) to develop an efficient and sustainable offering for urban mobility. ENI will be the first in Europe to provide…

WI Harper Group-backed RWDC Partners with Kimberly-Clark to Design Sustainable Alternatives to Traditional Plastics

WI Harper Group | June 8, 2021 | Source: PR Newswire In pursuit of its 2030 ambition to reduce the use of fossil fuel-based plastics by half before the end of the decade, Kimberly-Clark announced a partnership with WI Harper-backed biotech company RWDC Industries to advance sustainable technology for consumer products that provides much-needed solutions to the world’s…